Clareo Health | A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
A one arm study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable liver transplant patients converted from a tacrolimus (Prograf®) based immunosuppression regimen to a modified release tacrolimus based immunosuppression regimen.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is currently receiving Prograf ® based immunosuppressive therapy for liver transplantation.
Patient has stable whole blood trough level concentrations of Prograf® and is clinically stable
You may not be if
Patient has previously received an organ transplant other than a liver
Patient is currently receiving sirolimus immunosuppression therapy.
